Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corporation is positioned for a positive outlook due to its advancing orphan lung pipeline, which promises long-term diversification and growth opportunities beyond its established product offerings. The company is also implementing enhanced marketing and educational strategies aimed at healthcare professionals, which could further increase the uptake of its products, particularly Afrezza and Tyvaso DPI. With Tyvaso DPI gaining market share in pulmonary arterial hypertension and related conditions, along with the potential for increased royalty revenues, MannKind demonstrates substantial avenues for revenue generation and value creation.

Bears say

MannKind Corp's stock outlook appears negative due to growing competition and potential challenges in intellectual property protection, particularly following the approval of a competing product by SQ Innovation, which has led to a notable decline in MNKD's stock price. The company may also face share erosion and the necessity for price adjustments as it navigates potential setbacks related to trial outcomes, regulatory submissions, or adverse decisions that could impact the commercialization of its products. Additionally, while MannKind is developing innovative solutions, the presence of well-capitalized competitors with established products may further constrain its market position and pricing power.

MannKind (MNKD) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 6 analysts, MannKind (MNKD) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.